Previous 10 | Next 10 |
FLORHAM PARK, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team w...
Phathom Pharmaceuticals (NASDAQ:PHAT): Q3 GAAP EPS of -$0.98 beats by $0.03. Cash and cash equivalents were of $224M Press Release For further details see: Phathom Pharmaceuticals reports Q3 results
Two New Drug Applications (NDAs) for vonoprazan-based treatment regimens for H. pylori infection were accepted for filing by FDA with six-month Priority Review granted; PDUFA target action date of May 3, 2022 U.S. launch for both vonoprazan-based treatment regimens for H. py...
Phathom Pharmaceuticals (NASDAQ:PHAT) shares rise more than 10% premarket after the company announced the withdrawal of its previously announced primary and secondary public offering. The company had cash and cash equivalents of $225M as of September 30, 2021. Phathom expects c...
FLORHAM PARK, N.J., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the withdrawal of the previously...
Gainers: Siyata Mobile (NASDAQ:SYTA) +179%. AgriFORCE (NASDAQ:AGRI) +180%. China XD Plastics (NASDAQ:CXDC) +70%. Pasithea (NASDAQ:KTTA) +46%. Enphase (NASDAQ:ENPH) +28%. Kaival Brands (NASDAQ:KAVL) +25%. Leju Holdings (NYSE:LEJU) +24%. Volcon (NASDAQ:VLCN) +22%. Nurix (NASDAQ:NRIX) +22%. Guar...
FLORHAM PARK, N.J., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today an underwritten public offering of 5,...
Data from Phase 3 PHALCON-HP trial highlighted in oral presentation and recognized with the ACG Governors Award for Excellence in Clinical Research Phase 1 population PK data abstract concludes the large body of pre-existing clinical data related to vonoprazan in Asian populations...
FLORHAM PARK, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that data for vonoprazan, an investig...
Gainers: ION Geophysical (NYSE:IO) +42%. Valneva (NASDAQ:VALN) +33%. Progenity (NASDAQ:PROG) +31%. MeiraGTx (NASDAQ:MGTX) +30%. BTCS (NASDAQ:BTCS) +22%. Peabody Energy (NYSE:BTU) +20%. Evolving Systems (NASDAQ:EVOL) +18%. InMed (NASDAQ:INM) +16%. TORM (NASDAQ:TRMD) +17%. Aerovate (NASDAQ:AVTE...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
Phathom Pharmaceuticals Inc. Website:
VOQUEZNA is now approved and available to treat the largest category of Gastroesophageal Reflux Disease (GERD) VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA repre...
2024-06-23 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...